WP
KNSA icon

Woodline Partners’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Woodline Partners’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-19,005
Closed -$376K – 972
2024
Q4 		$376K Sell
19,005
-15,024
-44% -$343K ﹤0.01% 865
2024
Q3 		$850K Buy
+34,029
New +$829K 0.01% 515
2023
Q3 		– Sell
-290,001
Closed -$4.08M – 678
2023
Q2 		$4.08M Buy
+290,001
New +$3.88M 0.05% 326
2022
Q3 		– Sell
-332,893
Closed -$3.23M – 789
2022
Q2 		$3.23M Buy
+332,893
New +$3.11M 0.05% 323
2021
Q4 		– Sell
-234,357
Closed -$2.67M – 749
2021
Q3 		$2.67M Buy
+234,357
New +$3.05M 0.04% 367

Other funds holding KNSA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners's KNSA Position: Q1 2025 in Review

Woodline Partners sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2025, closing a stake of 19,005 shares — an estimated $376K sold.

Woodline Partners first reported a position in KNSA in Q3 2021 and held it in 5 quarters. The position peaked at $4.08M in Q2 2023. 176 funds tracked by Wall St. Rank hold KNSA as of Q1 2025.

  • Woodline Partners reported no remaining Kiniksa Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Woodline Partners sold 19,005 Kiniksa Pharmaceuticals shares in Q1 2025, an estimated $376K.
  • Woodline Partners first reported a position in Kiniksa Pharmaceuticals in Q3 2021 and held it in 5 quarters.
  • Woodline Partners's Kiniksa Pharmaceuticals position peaked at $4.08M in Q2 2023.
  • 176 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2025.

Based on Woodline Partners's 13F filing for Q1 2025, filed 15 May 2025.